四维[18F]FDG PET/CT的葡萄糖代谢率用于鉴别结节病病灶与恶性病灶
研究纳入100例心脏结节病患者和67例癌症患者,比较四维FDG PET/CT的SUV与葡萄糖代谢率(MRglc)鉴别结节病与恶性病灶的能力。结节病病灶SUV和MRglc均显著低于恶性病灶;MRglc的AUC为0.754,敏感度77%、特异度72%,优于SUV的AUC 0.703、敏感度64%、特异度75%。
要点
- 结节病病灶MRglc和SUV均显著低于恶性病灶(两者p<0.01)。
- MRglc鉴别结节病与恶性病灶AUC 0.754,优于SUV的AUC 0.703。
- MRglc阈值2.855时敏感度77%、特异度72%;SUV阈值5.025时敏感度64%、特异度75%。
核心结论
- 结节病病灶MRglc显著低于恶性病灶,MRglc较单独SUV提高了结节病病灶的识别能力。
研究设计与样本
- 纳入100例心脏结节病患者和67例癌症患者行四维FDG PET/CT,分析标准扫描SUV≥2.7的活跃病灶,用30至50分钟数据经线性Patlak分析直接重建得到SUV和MRglc,测量感兴趣体积(1.5 cm3)均值并以ROC分析评估诊断效能。
关键影像表现/征象
- 结节病病灶SUV为4.98 ± 2.00,恶性病灶为6.21 ± 2.14,结节病病灶较低(p<0.01)。
- 结节病病灶MRglc为2.52 ± 1.39 mg/min/100 mL,恶性病灶为3.68 ± 1.61 mg/min/100 mL,结节病病灶较低(p<0.01)。
诊断标准与关键数值
- MRglc鉴别结节病与恶性病灶的AUC为0.754,阈值2.855时敏感度77%、特异度72%。
- SUV鉴别结节病与恶性病灶的AUC为0.703,阈值5.025时敏感度64%、特异度75%。
临床应用与阅片要点
- MRglc较单独SUV提高了结节病淋巴结的识别能力,并有望通过省去延迟扫描缩短检查时间。
- MRglc可对恶性病灶进行准确评估和分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: On 18F-Fludeoxyglucose (FDG) PET/CT, active sarcoid lesions are often difficult to differentiate from malignant lesions. We investigated the potential of the glucose metabolic rate (MRglc, mg/min/100 mL), a new quantification of glucose metabolic kinetics derived from direct reconstruction based on linear Patlak analysis, to distinguish between sarcoidosis and malignant lesions.
MATERIALS AND METHODS: A total of 100 patients with cardiac sarcoidosis (CS) and 67 patients with cancer who underwent four-dimensional FDG PET/CT were enrolled. The lesions with a standardized uptake value (SUV) ≥ 2.7 on the standard scan were included as active lesions in the analysis. SUV and MRglc were derived using data acquired between 30 min and 50 min on four-dimensional FDG PET/CT. The mean value in the volume of interest (size 1.5 cm3) was measured. The diagnostic performance of sarcoidosis using MRglc and SUV was evaluated using receiver-operating-characteristic (ROC) analysis.
RESULTS: A total of 90 sarcoidosis lesions from 44 CS patients (18 males, 63.4 ± 12.2 years) and 87 malignant lesions from 57 cancer-bearing patients (32 males, 65 ± 14 years) were analyzed. SUV and MRglc for sarcoid lesions were significantly lower than those for malignant lesions (SUV, 4.98 ± 2.00 vs 6.21 ± 2.14; MRglc, 2.52 ± 1.39 vs 3.68 ± 1.61; p < 0.01). ROC analysis indicated that the ability to discriminate sarcoid patients from those with malignancy yielded areas under the curves of 0.703 and 0.754, with sensitivities of 64% and 77% and specificities of 75% and 72% for SUV 5.025 and MRglc 2.855, respectively.
CONCLUSION: MRglc was significantly lower in sarcoid lesions than malignant lesions, and improved sarcoid lesions identification over SUV alone.
CLINICAL RELEVANCE STATEMENT: MRglc improves sarcoid lymph node identification over SUV alone and is expected to shorten the examination time by eliminating delayed scans.
KEY POINTS: Active sarcoid lesions are sometimes associated with FDG accumulation and should be differentiated from malignant lesions. SUV and metabolic rate of glucose (MRglc) strongly positively correlated, and MRglc could differentiate sarcoid and malignant lesions. MRglc allows for accurate evaluation and staging of malignant lesions.
引用
- Inoue A, Nagao M, Kaneko K, et al. Glucose metabolic rate from four-dimensional [18F]FDG PET/CT to differentiate sarcoid lesions from malignant lesions. Eur Radiol. 2024. PMID: 39150487. doi:10.1007/s00330-024-11022-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。